The Trends in Peptide and Protein Sciences (Trends Pept. Protein Sci.) is a peer-reviewed, online-only (previously print-online), scientific journal owned by Protein Technology Research Center, Shahid Beheshti University of Medical Sciences and documents in all important aspects of the research in peptides and proteins focusing on analytics and impurities, bioinformatics, biopharmaceuticals and vaccines, biotechnology, chemical synthesis, conformational analysis, design and  development of protein therapeutics, determination of structure, enzymology, folding and sequencing,  formulation and stability, function, genetics,  immunology, kinetics, modeling, molecular biology, pharmacokinetics and pharmacodynamics of therapeutic proteins and antibodies, pharmacology,  protein engineering and development, protein-protein interaction, proteomics, purification/expression/production, simulation, thermodynamics and  hydrodynamics and protein biomarkers. The aim of this Journal is to publish high quality original research articles, reviews, short communications and letters and to provide a medium for scientists and researchers to share their findings from the area of peptides and proteins. The Trends in Peptide and Protein Sciences is published in collaboration with Iranian Association of Pharmaceutical Scientists.

The Trends in Peptide and Protein Sciences has been granted the Scientific-Research Rank  by the Commission of Medical Sciences Journals of Ministry of Health, Treatment and Medical Education of I.R. Iran.

 

Read More


Journal Info

Publisher:

Protein Technology Research Center, Shahid Beheshti University of Medical Sciences

Journal Name:

Trends in Peptide and Protein Sciences (TPPS)

Journal Abbreviation:

Trends Pept. Protein Sci.

eISSN:

2538-2446

Chairperson:

Reza Aboofazeli; PhD

Editor-in-Chief:

Bahram Kazemi; PhD

Managing Editor:

Maryam Tabarzad; PhD

Email:

tipps@sbmu.ac.ir

 

Call for Papers: Electronic Volume 6 (2021)

We are pleased to invite your manuscript submissions to the electronic volume 6 (2021) of Trends in Peptide and Protein Sciences (TPPS). Based on the new TPPS publication policies, articles will be continuously published online only from 2018 . ...

Read More


Indexing in Indexcopernicus (ICI Journals Master List)

We would like to inform that the journal „Trends in Peptide and Protein Sciences (ISSN: 2538-2535)” has passed the evaluation process positively and is indexed in the ICI Journals Master List database for 2019 . Based on the information submitted in the evaluation and the analysis of the issues of the journal from 2019, Index Copernicus Experts calculated TPPS Index Copernicus Value (ICV) for 2019. ICV 2019 = 74.91

Read More


Pectinase: Immobilization and Applications. A review

HaneefUr Rehman, Abdul Hameef Baloch, Muhammad Asif Nawaz

Trends in Peptide and Protein Sciences, Vol. 6 (2021), 24 February 2021 , Page 1-16 (e1)

Pectinase or pectinolytic enzyme is a complex enzyme with different catalytic units including polygalacturonase, pectin esterase and pectin lyase to degrade pectin polymers into different end products. The pectinase with degrading capability of pectin can be utilized in various industrial applications, such as clarification of fruits and vegetable juices, degumming of plant bast fibers, textile industries for removing non-cellulosic impurities, papermaking industries, wine clarification, coffee and tea fermentation, wastewater treatment, as well as, it is also used for the isolation of protoplasm in plant science research. Pectin derived oligosaccharides (POS) produced by pectinase are considered as prebiotic molecules.  However, the low operational stability in harsh industrial conditions confines the utilization of pectinase in industrial processes. Immobilization is the technique, which not only enhanced the stability of pectinase, but also, made the enzyme reusable for continuous industrial processes. The current review shares information about the pectinase and how the immobilization technology can enhance the industrial application of pectinase. Furthermore, various supports such as sodium alginate, agar-agar, polyacrylamide, aminated silica gel, nanocomposite microspheres, silica coated chitosan, nylon-6, porous glass etc. have been tested for the immobilization of pectinase through different methods, including entrapment, binding to a support and enzyme crosslinking. 


HIGHLIGHTS


  •  Pectinase is a complex enzyme with different catalytic units including polygalacturonase, pectin esterase and pectin lyase.

  • Pectinase immobilization enhanced the stability of pectinase and made the enzyme reusable for continuous industrial processes.

  • Entrapment, binding to a support and enzyme crosslinking are the common methods used for the immobilization of pectinase.

The Fabulous Impact of CRISPR Method in Sickle Cell Disease Treatment

Vida Ebrahimi, Atieh Hashemi

Trends in Peptide and Protein Sciences, Vol. 6 (2021), 24 February 2021 , Page 1-8 (e2)

Sickle cell diseases are the most prevalent monogenic blood diseases with complications such as severe end-organ harm, pain, and reduced life expectancy. Dealing options for sickle cell diseases are inadequate, as there are just two FDA-approved drugs to decrease acute manifestation. The only sickle cell diseases curative procedure is bone marrow transplantation, frequently from a harmonized, related donor. Ex vivo manipulation of autologous hematopoietic stem and progenitor cells and subsequent transplantation of genetically altered cells theoretically offer an everlasting therapy appropriate to all sickle cell anemia patients, regardless of the accessibility of fit donors and graft-versus-host disease. In this review, we emphasize applying CRISPR gene editing strategies for sickle cell anemia treatment, containing the genetic modification and rectification of sickle cell disease mutation in β-globin and the stimulation of fetal hemoglobin to protect cells against sickling. We summarize the importance of stem cell manipulation to cure sickle cell anemia having likely lifetime efficacy for cell and gene therapies.


HIGHLIGHTS
• Sickle cell disease (SCD) is a type of monogenic blood disorders.
• The CRISPR/Cas9 technology can be used to treat SCD.
• RBC sickling is reversed by mutation correction or fetal hemoglobin induction.

Browse
Keywords